By contrast, in two BL subtype cell lines, MDA-MB-468 and SUM149PT, treatment of gefitinib or PI-103 as single agents induced increased activity of caspase-3/7 and the combination of gefitinib/PI-103 markedly increased caspase-3/7 activity (Fig. 5A). The gene discussed is CASP3; the disease is Burkitt lymphoma.